Last reviewed · How we verify

Tedivax-Adult™/ Td-Rix™

GlaxoSmithKline · Phase 3 active Biologic

Tedivax-Adult/Td-Rix is a combined tetanus and diphtheria toxoid vaccine that stimulates the immune system to produce antibodies against tetanus and diphtheria toxins.

Tedivax-Adult/Td-Rix is a combined tetanus and diphtheria toxoid vaccine that stimulates the immune system to produce antibodies against tetanus and diphtheria toxins. Used for Active immunization against tetanus and diphtheria in adults, Booster vaccination in adults with prior tetanus/diphtheria immunization.

At a glance

Generic nameTedivax-Adult™/ Td-Rix™
SponsorGlaxoSmithKline
Drug classToxoid vaccine
TargetTetanus toxin (tetanospasmin) and diphtheria toxin
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains inactivated toxins from Clostridium tetani and Corynebacterium diphtheriae, which trigger adaptive immune responses without causing disease. These toxoids prime B cells and T cells to recognize and neutralize the actual toxins if exposure occurs, providing long-term protective immunity against tetanus and diphtheria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: